Certainly better than ever now. HALO doesn't really need the money if, initially, they only intend to push PEG to market for pancan and have a few Ph2s in the works. If they sell ex-US rights, I hope it leaves a substantial percentage still with HALO and the money used to finance more PEG trials.
I am still leery about having too many partnerships with one company. It just makes it too easy for the big guy to scoop up the little guy on the cheap. For that reason, I would NEVER want HALO to sell stock to big pharma as part of any deal. Pharma would use that leverage to keep the price down.
I believe Roche's ownership of Genentech stock suppressed the price of the eventual buyout of the other half years ago. (although I think I remember them at least giving shareholders a chance to increase our holdings before buyout) I can think of several other tiny companies I've owned where the stock price seemed frozen the year before buyout as the short interest grew. Yes, these might be the paranoid ravings of a mad investor ;-) but I would swear some off-shore company was acting in cahoots with the acquiring pharma company and essentially shorting against their substantial holdings of the little biotech.
I believe HALO has savvy management and a few large investors, like Kirk, who would be aware of this issue.
News 
Market Data 
Discover 
